Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the SVGO/ASCO.

Meier, Christian; Uebelhart, Brigitte; Aubry-Rozier, Bérengère; Birkhäuser, Martin; Bischoff-Ferrari, Heike A; Frey, Diana; Kressig, Reto W; Lamy, Olivier; Lippuner, Kurt; Stute, Petra; Suhm, Norbert; Ferrari, Serge (2017). Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the SVGO/ASCO. Swiss medical weekly, 147(w14484), w14484. EMH Schweizerischer Ärzteverlag 10.4414/smw.2017.14484

Preview

Text smw_147_w14484.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (605kB) | Preview

Antiosteoporotic drugs are recommended in patients with fragility fractures and in patients considered to be at high fracture risk on the basis of clinical risk factors and/or low bone mineral density. As first-line treatment most patients are started with an antiresorptive treatment, i.e. drugs that inhibit osteoclast development and/or function (bisphosphonates, denosumab, oestrogens or selective oestrogen receptor modulators). In the balance between benefits and risks of antiresorptive treatment, uncertainties remain regarding the optimal treatment duration and the management of patients after drug discontinuation. Based on the available evidence, this position statement will focus on the long-term management of osteoporosis therapy, formulating decision criteria for clinical practice.

Interest & Impact

Downloads

247 since deposited on 05 Dec 2017
24 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item